Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer

Satoshi Katayama, Victor M. Schuettfort, Benjamin Pradère, Keiichiro Mori, Hadi Mostafaei, Fahad Quhal, Reza Sari Motlagh, Ekaterina Laukhtina, Nico C. Grossmann, Abdulmajeed Aydh, Paweł Rajwa, Frederik König, Pierre I. Karakiewicz, Martin Haydter, Marco Moschini, Mohammad Abufaraj, Yair Lotan, Richard K. Lee, Quoc‐Dien Trinh, Éva Compérat, Jeremy Yuen‐Chun Teoh, Yasutomo Nasu, Shahrokh F. ShariatJournal of Cancer Research and Clinical Oncology 2022 · DOI

Abstract: Preoperative HGF identified MIBC patients who harbored features of clinically and biologically aggressive disease. Plasma HGF could serve, as part of a panel, as a biomarker to aid in preoperative treatment planning regarding intensity of treatment in patients with clinical MIBC.

The Challenge of MIBC Risk Stratification

Muscle-invasive bladder cancer (MIBC) presents a significant clinical challenge. The standard of care—neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC)—is effective but fraught with toxicity. The primary difficulty lies in risk stratification: current clinical staging often fails to accurately identify which patients harbor aggressive, non-organ-confined (NOC) disease. This diagnostic gap leads to both overtreatment of patients who may not require toxic chemotherapy and undertreatment of those with underestimated aggressive disease. This study investigates whether circulating hepatocyte growth factor (HGF), a cytokine critical to tumor invasion and angiogenesis, can serve as a reliable preoperative biomarker to guide treatment intensity.

Methodology

This retrospective multi-institutional study analyzed a cohort of 565 MIBC patients who underwent radical cystectomy. Plasma HGF levels were quantified using a commercially available ELISA from blood samples collected on the morning of surgery.

Researchers utilized logistic regression to predict pathological outcomes, such as lymph node (LN) metastasis and NOC disease, while Cox regression models were employed to predict survival outcomes, including Recurrence-Free Survival (RFS), Overall Survival (OS), and Cancer-Specific Survival (CSS). The predictive accuracy was evaluated using the Area Under the Curve (AUC) and the Concordance index (C-index). Furthermore, Decision Curve Analysis (DCA) and Minimal Clinically Important Difference (MCID) were applied to assess the real-world clinical utility of adding HGF to standard clinical models.

Key Insights: The HGF/MET Axis and Clinical Utility

The study reinforces the biological significance of the HGF/MET pathway in oncology. Elevated plasma HGF levels are not merely statistical markers but reflect the active "invasive machinery" of the tumor.

Conceptual model of the added benefit of neoadjuvant chemotherapy (NAC) on cancer-specific survival (CSS) stratified by HGF levels.

A critical finding was that HGF provides independent prognostic value. When added to standard preoperative models (including age, sex, and clinical stage), HGF improved the predictive accuracy for non-organ-confined disease by 8%. As illustrated in the conceptual model above, patients with high HGF levels may derive a significantly greater benefit from NAC (18% added CSS) compared to those with low HGF levels (10% added CSS), highlighting its potential to refine patient selection for intensive therapy.

Key Results and Decision Curve Analysis

The analysis revealed several significant associations:

  • Pathology Prediction: Higher HGF levels were significantly linked to an increased risk of LN metastasis (OR 1.21) and NOC disease (OR 1.35).
  • Survival Outcomes: Patients with HGF levels exceeding the median (512.3 pg/mL) experienced significantly worse survival. The inclusion of HGF in preoperative models improved accuracy for RFS and CSS by 6% and 5%, respectively.
  • Net Benefit: DCA demonstrated that approximately half of the patients would experience a net benefit in treatment planning if HGF measurements were integrated into their preoperative workup.
Decision Curve Analysis (DCA) demonstrating the net benefit of adding plasma HGF to standard clinical models for predicting pathological and survival outcomes.

Limitations and Future Directions

Despite these promising results, the study acknowledges several limitations. The retrospective design introduces potential selection biases, and the lack of a standardized "universal" cut-off for HGF levels complicates immediate clinical implementation. Additionally, surgical variability across the multi-institutional cohort, such as the extent of lymph node dissection, was not standardized.

Future research should focus on integrating HGF into a multi-marker panel. Combining HGF with other circulating biomarkers or genomic data could provide the necessary precision to move toward truly individualized treatment strategies for bladder cancer patients.

Summary updated

Abstract

Preoperative HGF identified MIBC patients who harbored features of clinically and biologically aggressive disease. Plasma HGF could serve, as part of a panel, as a biomarker to aid in preoperative treatment planning regarding intensity of treatment in patients with clinical MIBC.
BibTeX
@article{katayama2022prognostic,
  author = {Satoshi Katayama and Victor M. Schuettfort and Benjamin Pradère and Keiichiro Mori and Hadi Mostafaei and Fahad Quhal and Reza Sari Motlagh and Ekaterina Laukhtina and Nico C. Grossmann and Abdulmajeed Aydh and Paweł Rajwa and Frederik König and Pierre I. Karakiewicz and Martin Haydter and Marco Moschini and Mohammad Abufaraj and Yair Lotan and Richard K. Lee and Quoc‐Dien Trinh and Éva Compérat and Jeremy Yuen‐Chun Teoh and Yasutomo Nasu and Shahrokh F. Shariat},
  title = {{Prognostic value of hepatocyte growth factor for muscle-invasive bladder cancer}},
  journal = {Journal of Cancer Research and Clinical Oncology},
  year = {2022},
  doi = {10.1007/s00432-021-03887-x},
}
Figure